Approval opens the gate; adoption depends on clinicians choosing to prescribe and patients choosing to take the drug, and both can decline.
Why a clinician might hesitate
Prescribing is a judgment made under time pressure with incomplete information. An unfamiliar design method and thinner-than-usual evidence raise the perceived risk of the choice, so a clinician may prefer a familiar drug even when the new one is approved.
Why a patient might hesitate
A patient who sees a treatment as experimental may decline it, particularly when a conventional option is available. If the drug is not taken as prescribed, its real-world benefit shrinks, which feeds back into how the next patient and clinician judge it.